270 related articles for article (PubMed ID: 23469252)
1. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.
Ulla M; Bonny JM; Ouchchane L; Rieu I; Claise B; Durif F
PLoS One; 2013; 8(3):e57904. PubMed ID: 23469252
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2*/MRI.
Wieler M; Gee M; Martin WR
Parkinsonism Relat Disord; 2015 Mar; 21(3):179-83. PubMed ID: 25534153
[TBL] [Abstract][Full Text] [Related]
3. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X
Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399
[TBL] [Abstract][Full Text] [Related]
4. MRI assessment of basal ganglia iron deposition in Parkinson's disease.
Wallis LI; Paley MN; Graham JM; Grünewald RA; Wignall EL; Joy HM; Griffiths PD
J Magn Reson Imaging; 2008 Nov; 28(5):1061-7. PubMed ID: 18972346
[TBL] [Abstract][Full Text] [Related]
5. Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.
Bergsland N; Zivadinov R; Schweser F; Hagemeier J; Lichter D; Guttuso T
Mov Disord; 2019 Jul; 34(7):1006-1013. PubMed ID: 31180615
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
[TBL] [Abstract][Full Text] [Related]
7. Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD).
Esterhammer R; Seppi K; Reiter E; Pinter B; Mueller C; Kremser C; Zitzelsberger T; Nocker M; Scherfler C; Poewe W; Schocke M
PLoS One; 2015; 10(12):e0145493. PubMed ID: 26713760
[TBL] [Abstract][Full Text] [Related]
8. Iron and neuromelanin imaging in basal ganglia circuitry in Parkinson's disease with freezing of gait.
Zhang Y; Zhang C; Wang X; Liu Y; Jin Z; Haacke EM; He N; Li D; Yan F
Magn Reson Imaging; 2024 Sep; 111():229-236. PubMed ID: 38777243
[TBL] [Abstract][Full Text] [Related]
9. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.
Gorell JM; Ordidge RJ; Brown GG; Deniau JC; Buderer NM; Helpern JA
Neurology; 1995 Jun; 45(6):1138-43. PubMed ID: 7783878
[TBL] [Abstract][Full Text] [Related]
10. Freezing of gait in early Parkinson's disease: Nigral iron content estimated from magnetic resonance imaging.
Wieler M; Gee M; Camicioli R; Martin WR
J Neurol Sci; 2016 Feb; 361():87-91. PubMed ID: 26810522
[TBL] [Abstract][Full Text] [Related]
11. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
[TBL] [Abstract][Full Text] [Related]
12. Increased iron in the substantia nigra pars compacta identifies patients with early Parkinson'sdisease: A 3T and 7T MRI study.
Alushaj E; Handfield-Jones N; Kuurstra A; Morava A; Menon RS; Owen AM; Sharma M; Khan AR; MacDonald PA
Neuroimage Clin; 2024; 41():103577. PubMed ID: 38377722
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
Geng DY; Li YX; Zee CS
Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Susceptibility Mapping in Parkinson's Disease.
Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of QSM over R2* in assessment of parkinson's disease - A systematic review.
Saikiran P;
Neurol India; 2020; 68(2):278-281. PubMed ID: 32415005
[TBL] [Abstract][Full Text] [Related]
17. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
Graham JM; Paley MN; Grünewald RA; Hoggard N; Griffiths PD
Brain; 2000 Dec; 123 Pt 12():2423-31. PubMed ID: 11099445
[TBL] [Abstract][Full Text] [Related]
18. Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease.
He N; Langley J; Huddleston DE; Chen S; Huang P; Ling H; Yan F; Hu X
Neuroimage Clin; 2020; 28():102391. PubMed ID: 32889398
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease.
Ryvlin P; Broussolle E; Piollet H; Viallet F; Khalfallah Y; Chazot G
Arch Neurol; 1995 Jun; 52(6):583-8. PubMed ID: 7763206
[TBL] [Abstract][Full Text] [Related]
20. Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson's disease.
Kim M; Yoo S; Kim D; Cho JW; Kim JS; Ahn JH; Mun JK; Choi I; Lee SK; Youn J
Neurol Sci; 2021 Dec; 42(12):5297-5304. PubMed ID: 33860863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
